Home/Pipeline/AZD7789

AZD7789

Advanced Solid Tumors

Phase I/IIActiveN/A

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase I/II

Status

Active

Company

AstraZeneca

About AstraZeneca

AstraZeneca is a global biopharmaceutical leader with a mission to push the boundaries of science to deliver life-changing medicines. The company has achieved significant commercial success with 16 blockbuster drugs and a robust pipeline of 197 projects, underpinned by a 'Growth Through Innovation' strategy focused on disease biology, next-generation therapeutics, predictive clinical success, and clinical innovation. AstraZeneca's strategic integration of data science, AI, and novel therapeutic modalities positions it to maintain its competitive edge and address complex healthcare challenges across its core therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Cardiovascular/Renal/Metabolic Respiratory & Immunology Rare Disease Vaccines & Immune Therapies

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active